---
title: An FDA Panel Voted to Let Pharmacies Compound BPC-157, Against the Agency's Own Reviewers
description: An FDA advisory committee voted 8-6-1 to recommend letting pharmacies compound the peptide BPC-157, over FDA staff objections. It is still not approved.
author: Dr Marina Nani (Editor-in-Chief)
updated: 2026-09-08T21:20:02.430Z
canonical: https://richhealthmagazine.com/article/fda-panel-backs-bpc-157-compounding-vote
image: https://cdn.nanimediahouse.com/bpc-157-fda-compounding-vote-272318.webp
categories: Longevity & Science
content_type: News
region: United States
publication: Rich Health Magazine
schema_type: Article
---

An FDA advisory committee has recommended that compounding pharmacies be allowed to use BPC-157, a synthetic peptide sold widely online and marketed to athletes for injury recovery. The Pharmacy Compounding Advisory Committee [voted 8-6-1 on July 23 and 24, 2026](https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html) to recommend adding both the free base and acetate forms of BPC-157 to the FDA's Section 503A Bulks List, the list of bulk ingredients that compounding pharmacies are allowed to use. The committee took that step over the objection of the FDA's own review staff, who had recommended against it.

The vote is a recommendation, not a rule. It is non-binding, formal FDA rulemaking is still pending, and BPC-157 is still not FDA approved. Even if the agency later follows the committee, a pharmacy-compounded preparation of BPC-157 would not be an FDA-approved drug. It would only mean that compounding pharmacies could legally use the substance as a bulk ingredient.

## The Panel Backed BPC-157 Against FDA Staff Advice

FDA review staff had recommended against adding these peptides, citing insufficient safety and efficacy data and gaps in how the substances have been characterized. BPC-157 was one of six peptides the panel backed at the two-day meeting. The vote was close at 8-6-1, and the recommendation carries no legal force on its own. The FDA now decides whether to write it into a rule.

The vote follows several years of regulatory back-and-forth. In September 2023 the FDA placed BPC-157 and several other peptides in "category 2," a designation for substances that raise significant safety concerns for compounding, which restricted their use. The peptide was later removed from that category, and the July 2026 vote is the next step in the process.

## The Vote Does Not Make BPC-157 Legal to Buy

BPC-157 is an unapproved drug, and the committee's recommendation does not change its legal status. It is [prohibited by the World Anti-Doping Agency](https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products) for athletes at all times and is banned by the US Department of Defense.

The peptide is nonetheless sold widely on the gray market, online and to athletes and biohackers who take it for recovery. Products sold that way are not FDA-approved medicines and are not subject to the manufacturing oversight that approved drugs and licensed compounding both require.

## The Human Evidence Is Thin

Most of what is known about BPC-157 comes from laboratory and animal studies rather than from people. A 2025 systematic review in HSS Journal screened 544 papers and included 36 studies, of which 35 were preclinical and one was a human case review. The review found no controlled human trials and no human clinical safety data.

Independent reporting has [described the evidence as thin and mostly preclinical](https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/), and the FDA in 2023 flagged potential safety risks, including unknown impurities and a theoretical concern that the peptide's effect on blood-vessel growth could in principle promote tumor growth.

## The FDA Is Tightening Other Compounding at the Same Time

The recommendation does not mean the FDA is easing up on compounding across the board. Around the same time, the agency moved to [tighten the compounding of GLP-1 weight-loss drugs](https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html). A committee has backed one peptide for compounding even as the FDA restricts another popular class of compounded drugs, so the overall direction is mixed rather than a broad loosening.

## FAQ

**Q: Is BPC-157 FDA approved?**
No. BPC-157 is not an FDA-approved drug. The July 2026 committee vote was a non-binding recommendation to let compounding pharmacies use it, and even a compounded preparation would not be an FDA-approved drug.

**Q: What is the 503A Bulks List?**
It is the FDA's list of bulk drug substances that compounding pharmacies are permitted to use when preparing customized medications. The advisory committee recommended adding BPC-157 to it, which the FDA has not yet done through rulemaking.

**Q: What did the FDA advisory committee vote actually change?**
On its own, nothing legally binding. The panel voted 8-6-1 to recommend adding BPC-157 to the 503A Bulks List, over the objection of FDA review staff. Formal FDA rulemaking is still pending, and the substance's approval and legal status are unchanged for now.

**Q: Is BPC-157 legal to buy?**
BPC-157 is an unapproved drug, and the products sold online and on the gray market are not FDA-approved medicines. The committee's recommendation did not change that.

**Q: Is BPC-157 banned for athletes?**
Yes. It is prohibited by the World Anti-Doping Agency at all times and is banned by the US Department of Defense.

**Q: How strong is the evidence behind BPC-157?**
It is thin and mostly from animal and laboratory studies. A 2025 systematic review in HSS Journal found no controlled human trials and no human clinical safety data, and the FDA has flagged potential safety concerns.